NEW YORK, April 24 - Yamanouchi pharmaceuticals, Japan's third-largest drugmaker, plans to double its commitment to genomics over the next five years to 50 billion yen, or $411.8 million, Reuters reported from Tokyo on Tuesday.

The Tokyo-based company, which has invested four to five billion yen annually over the last few years, said it hopes to invest in genomics in order to find new drug targets and to catch up with US rivals, Reuters said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.